Buscar en
Revista Colombiana de Psiquiatría (English Edition)
Toda la web
Inicio Revista Colombiana de Psiquiatría (English Edition) Reversible alopecia secondary to OROS methylphenidate
Journal Information
Vol. 49. Issue 3.
Pages 208-210 (July - September 2020)
Share
Share
Download PDF
More article options
ePub
Visits
0
Vol. 49. Issue 3.
Pages 208-210 (July - September 2020)
Case Report
DOI: 10.1016/j.rcpeng.2018.09.003
Reversible alopecia secondary to OROS methylphenidate
Alopecia reversible secundaria a metilfenidato OROS
Visits
...
Marta Núñez-Garces
Corresponding author
mngarces75@gmail.com

Corresponding author.
, Agustín Sánchez-Gayango, Cristina Romero-Pérez
Unidad de Gestión Clínica de Salud Mental, Área de Gestión Sanitaria Sur de Sevilla, Hospital Universitario Nuestra Señora de Valme, Sevilla, Spain
Article information
Abstract
Full Text
Bibliography
Download PDF
Statistics
Abstract
Introduction

Attention deficit hyperactivity disorder has a prevalence of 1–4% of the Spanish school population. Its treatment consists of giving amphetamine derivatives and, recently, non-stimulant drugs, without finding any differences in efficacy in the studies performed.

Clinical case

A 7-year-old girl was referred from neurology due to learning delay and behaviour disorders. Diagnosed as likely ADHD, treatment was started with immediate release methylphenidate, and later with an osmotic release oral system (OROS) methylphenidate. When alopecia areata appeared, this treatment was withdrawn. After the re-introduction of modified release methylphenidate 30:70, symptom control was achieved without the appearance of alopecia.

Discussion

There is a published history of two cases of alopecia areata with OROS methylphenidate that resolved after increasing the dose of the drug without clearly knowing the reason for this event. There is no consensus on the priority use of the immediate release formula or the OROS methylphenidate.

Keywords:
OROS methylphenidate
Alopecia areata
Side effects
ADHD
RESUMEN
Introducción

El TDAH tiene una prevalencia del 1–4% de la población escolar española. Su tratamiento se realiza con derivados anfetamínicos y, recientemente, con fármacos no estimulantes; los estudios realizados no han encontrado diferencias de eficacia.

Caso clínico

Niña de 7 años llegó derivada desde neurología por retraso en el aprendizaje y trastornos de conducta. Orientada como TDAH, se inició tratamiento con metilfenidato de liberación inmediata y posteriormente con la fórmula OROS; apareció alopecia areata y se retiró el tratamiento. Tras la reintroducción de metilfenidato de liberación modificada 30:70, se consiguió controlar los síntomas sin que apariciera alopecia.

Discusión

Hay antecedentes publicados de 2 casos de alopecia areata con metilfenidato OROS, que se resolvieron tras el aumento de dosis del fármaco, aunque no se conoce claramente el motivo de este suceso. No hay consenso sobre el uso prioritario de la fórmula de liberación inmediata o la fórmula OROS del metilfenidato.

Palabras clave:
Metilfenidato OROS
Alopecia areata
Efectos secundarios
TDAH

Article

These are the options to access the full texts of the publication Revista Colombiana de Psiquiatría (English Edition)
Subscriber
Subscriber

If you already have your login data, please click here .

If you have forgotten your password you can you can recover it by clicking here and selecting the option “I have forgotten my password”
Purchase
Purchase article

Purchasing article the PDF version will be downloaded

Price 19.34 €

Purchase now
Contact
Phone for subscriptions and reporting of errors
From Monday to Friday from 9 a.m. to 6 p.m. (GMT + 1) except for the months of July and August which will be from 9 a.m. to 3 p.m.
Calls from Spain
932 415 960
Calls from outside Spain
+34 932 415 960
E-mail
Article options
Tools